{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:58:19Z","timestamp":1753891099540,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>CD7-targeted chimeric antigen receptor-T (CAR-T) cell therapy has shown great promise in the treatment of relapsed\/refractory T-cell acute lymphoblastic leukemia (T-ALL). In this study, we reported a case of a 34-year-old male patient with T-ALL who finally developed multi-line drug resistance and refractoriness after multiple lines of high-intensity chemotherapy. After physician evaluation, this patient received allogeneic hematopoietic stem cell transplantation (allo-HSCT). Then, The patient remained in complete remission (CR) for four months before a relapse with 26.64% chimerism rate, so he was treated with allogeneic anti-CD7 CAR-T cells after chemotherapy reducing the tumor burden. The CAR-T product was a novel anti-CD7 CAR-T based on retroviral vectors (RV). After infusion, the patient achieved CR within 1 month after anti-CD7 CAR-T infusion and the remission has been ongoing for 9 months to date. Cytokine release syndrome (CRS) 1 was experienced while no immune effector cell-associated neurotoxicity syndrome (ICANS) was found. In addition, CAR copy number peaked at 350, 758 copies\/\u03bcg on day 6. This case report of clinical treatment of T-ALL with anti-CD7 CAR-T cells prepared using a retroviral vector without gene editing and combined with chemotherapy, which demonstrated that the RV-based anti-CD7 CAR-T cells had good therapeutic effect and high safety in triple-refractory T-ALL patients.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1519055","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T06:11:57Z","timestamp":1736835117000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report: The case of T-cell acute lymphoblastic leukemia treated with chemotherapy followed by anti-CD7 CAR-T cells using retroviral vector"],"prefix":"10.3389","volume":"15","author":[{"given":"Huanhuan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qihong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengdi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaru","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongyou","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaxiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.8.3154","article-title":"Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity","volume":"90","author":"Ott","year":"1997","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164266","article-title":"Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia","volume":"322","author":"Mullighan","year":"2008","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-692608","article-title":"Management of adults with T-cell lymphoblastic leukemia","volume":"129","author":"Marks","year":"2017","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell Malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e005701","DOI":"10.1136\/jitc-2022-005701","article-title":"Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL","volume":"11","author":"Song","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e247065","DOI":"10.6004\/jnccn.2024.7065","article-title":"The role of CAR T-cell therapy in relapsed\/refractory adult B-ALL","volume":"22","author":"Othman","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0285-8","article-title":"CAR T-cells for T-cell Malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells","volume":"32","author":"Alcantara","year":"2018","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T-cell Malignancies using anti-CD5 chimeric antigen receptor","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell Malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell Malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Zheng","year":"2021","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.150.5.2081","article-title":"CD7- T cells represent a subset of normal human blood lymphocytes","volume":"150","author":"Reinhold","year":"1993","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0065-5","article-title":"An\u00a0\u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic\u00a0Malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014498","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2124627","DOI":"10.1155\/2022\/2124627","article-title":"A promising insight: the potential influence and therapeutic value of the gut microbiota in GI GVHD","volume":"2022","author":"Li","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3400","article-title":"Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease","volume":"17","author":"Mathewson","year":"2016","journal-title":"Nat Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101430","DOI":"10.1016\/j.smim.2020.101430","article-title":"New viral vectors for infectious diseases and cancer","volume":"50","author":"Sasso","year":"2020","journal-title":"Semin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1186\/s12967-022-03729-5","article-title":"Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products","volume":"20","author":"Shao","year":"2022","journal-title":"J Transl Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"112174","DOI":"10.1016\/j.intimp.2024.112174","article-title":"Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report","volume":"134","author":"Zhong","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e36955","DOI":"10.1016\/j.heliyon.2024.e36955","article-title":"The first case of multiple myeloma treated with ASCT followed by Anti-BCMA CAR-T cells using retrovirus vector: A case report","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1519055\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T06:12:01Z","timestamp":1736835121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1519055\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2024.1519055"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1519055","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"article-number":"1519055"}}